AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Sees Significant Decline in Short Interest

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a large decrease in short interest in June. As of June 15th, there was short interest totaling 3,204,092 shares, a decrease of 54.3% from the May 31st total of 7,013,343 shares. Currently, 22.0% of the company’s shares are sold short. Based on an average daily volume of 51,555,532 shares, the days-to-cover ratio is currently 0.1 days.

AIM ImmunoTech Stock Performance

AIM opened at $0.31 on Monday. The firm has a market capitalization of $4.54 million, a P/E ratio of -0.05 and a beta of 1.18. The firm’s 50 day moving average is $0.44 and its 200-day moving average is $0.82. AIM ImmunoTech has a 52-week low of $0.21 and a 52-week high of $20.35. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.10.

AIM ImmunoTech (NYSEAMERICAN:AIM) last posted its earnings results on Friday, May 15th. The company reported ($0.69) EPS for the quarter. The firm had revenue of $0.02 million for the quarter. Analysts expect that AIM ImmunoTech will post -0.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets reduced their price target on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $9.00.

Hedge Funds Weigh In On AIM ImmunoTech

A number of institutional investors have recently added to or reduced their stakes in AIM. Corient Private Wealth LLC acquired a new stake in shares of AIM ImmunoTech during the second quarter valued at about $87,000. Sabby Management LLC purchased a new stake in shares of AIM ImmunoTech during the third quarter worth about $79,000. Finally, DRW Securities LLC lifted its stake in shares of AIM ImmunoTech by 60.6% in the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after acquiring an additional 26,254 shares in the last quarter. Institutional investors and hedge funds own 12.02% of the company’s stock.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.